Aviso: Esta noticia tiene más de un año. Última actualización: 15/11/2009 21:01
This press release contains certain forward-looking statements about Efient for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndromes who are managed with percutaneous coronary intervention and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialisation. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that the product will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward-looking statements.
Efient(R) is a registered trademark of Eli Lilly and Company.
Plavix(R) is a registered trademark of Sanofi-Aventis Corp.
VerifyNow(R) is a registered trademark of Accumetrics.
P--LLY
1 American Heart Association. Diabetes Mellitus-Statistics-2009 Update. http://www.americanheart.org/downloadable/heart/1236357007811FS12DIAB08.pdf
2 Young, L, Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial. JAMA, 2009;301(15):1547-1555.
3 Cleveland Clinic. Understanding Coronary Artery Disease. Available at: http://my.clevelandclinic.org/heart/disorders/cad/understandingcad.aspx. Last accessed on October 29, 15 Nov. (Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO ) -
Derin Denham, Eli Lilly and Company, +1-317-277-6749, or Cell, +1-317-370-1435; Dr. Michaela Paudler-Debus, Daiichi Sankyo Europe GmbH, +49-(0)89-78-08-685, or Cell, +49-(0)172-845-8974; Shigemichi Kondo, Daiichi Sankyo (Tokyo), +81-3-6225-1126